Drugs / Chimeric antigen receptor modified γδ T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04702841 | Jun 2020 → Jun 2022 | cancer | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chimeric antigen receptor modified γδ T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04702841 ↗ |
| Known as | CAR - γ δ T Cells | “Clinical Application of Chimeric Antigen Receptor Modified γδ T Cells（CAR - γ δ T Cells） in Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors” NCT04702841 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor modified γδ T cells” NCT04702841 ↗ |
| Route | Intravenous | “Infusion,iv,0.2-5 ×10\^6/ kg,once.” NCT04702841 ↗ |